Noctrix Health, Inc., a Pleasonton, CA-based medical device company, closed a $40M Series C financing.
The round was led by Sectoral Asset Management with participation from other new investors Angelini Ventures, ResMed, and Asahi Kasei Corporation and insiders OrbiMed and Treo Ventures.
The company intends to use the funds to advance the Nidra™ Tonic Motor Activation (TOMAC) therapy towards its anticipated launch in the US market.
Led by Founder and CEO Shri Raghunathan, Noctrix Health is a medical device company committed to developing clinically validated medical technologies that improve the quality of life for patients with chronic conditions. The Nidra™ Tonic Motor Activation (TOMAC) system is a non-pharmacologic, wearable treatment intended to reduce symptoms of primary moderate-severe Restless Legs Syndrome (RLS) and improve sleep quality in adults refractory to medications. It is available in the US by prescription only.
FinSMEs
16/01/2024